Naredo-Gonzalez, Gregorio
Upreti, Rita
Jansen, Maurits A.
Semple, Scott
Sutcliffe, Oliver B.
Marshall, Ian
Walker, Brian R.
Andrew, Ruth
Funding for this research was provided by:
Wyeth Pharmaceuticals (CVMD/EU/016, CVMD/EU/016, CVMD/EU/016, CVMD/EU/016)
British Heart Foundation (RG/11/4/28734, RG/11/4/28734)
Article History
Received: 27 September 2021
Accepted: 18 August 2022
First Online: 29 September 2022
Competing interests
: BRW is a holder of a relevant patent for use of 11β-hydroxysteroid dehydrogenase 1 inhibitors. All other authors do not have any competing interests to declare.